NCT07301658

Efficacy and Safety of Revodiol Calming Cream® in Atopic Dermatitis.

Evaluation of the Effectiveness and Safety of Revodiol Calming Cream® in the Management of Atopic Dermatitis Under Dermatological Control.

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 42 (actual)
• Sponsor: i+Med S.Coop. · Industry
• Sex: All
• Age: —
• Healthy volunteers: Accepted

Summary

A 56-day clinical study evaluated Revodiol Calming Cream on pediatric and adult participants with mild to moderate atopic-prone skin under dermatological supervision. The product was applied twice daily, and efficacy was assessed through dermatological scoring, instrumental measurements, and subjective questionnaires. Results aimed to show improvements in barrier function, hydration, skin texture, and reduction of erythema, dryness, and pruritus, with feedback on comfort and quality of life.

Conditions

• Atopic Dermatitis (AD)

Interventions

Type	Name	Description
OTHER	Novel dermocosmetic product containing cannabidiol (CBD) and Annona cherimola fruit extract.	Apply twice a day on the affected skin area to protect it, previously cleaned and dried. No rinsing is required. Volunteers were instructed not to use any other cosmetic product in the study area until the end of the study.

Timeline

• Start date: 2023-02-27
• Primary completion: 2023-06-06
• Completion: 2024-08-07
• First posted: 2025-12-24
• Last updated: 2025-12-24

Locations

1 site across 1 country: Spain